News | March 14, 2026
Curatis and Neupharma strike major deal to bring brain tumor therapy to Japan
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Giredestrant shows promise despite missing primary goal
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Germany will be the first launch market
The first of four planned modules at the new plant is expected to come online by summer 2026
Subscribe To Our Newsletter & Stay Updated
